The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Oncternal Therapeutics, Inc(NASDAQ:ONCT) 
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in ...
Website: http://www.oncternal.com
Founded: 1997
Full Time Employees: 11
CEO: James B. Breitmeyer
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
Oncternal Therapeutics Days Payable Outstanding ttm (DPO)
Oncternal Therapeutics Days Receivable Outstanding ttm (DSO)
Oncternal Therapeutics Days Inventory Outstanding ttm (DIO)
Oncternal Therapeutics Op Cashflow Per Share ttm
Oncternal Therapeutics Free Cashflow Per Share ttm
Oncternal Therapeutics Cash Per Share ttm
Oncternal Therapeutics P/S ratio ttm
Oncternal Therapeutics (GAAP) P/E ratio ttm
Oncternal Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.